[Pharmacology of DTIC (author's transl)].
DTIC, a new cytostatic drug developed by the NCI-USA, is described and some relevant pharmacological characteristics are defined. This drug was proved to be the number one choice for the treatment of malignant melanoma and of sarcomas. It also appears to be of value in advanced cases of Hodgkins disease. DTIC represents a very valuable addition to the available drugs for chemotherapy of malignant tumours.
D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D003606:Dacarbazine / Q000494:pharmacology*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy; D014226:Triazenes / Q000494:pharmacology*
D014226:Triazenes; D003606:Dacarbazine
Zur Pharmakologie des DTIC.